Monday, November 23, 2009, 8:43pm EST - Canadian Markets are closed.
To create a watchlist or portfolio of shares, Sign-in or Register

Cerus Corporation (CERS)

 At 16:00 EST: 1.98 USD  Down 0.02 (1.00%)  
MORE ON CERS
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Cerus Corporation (NGM:CERS) Delayed quote dataEdit
Last Trade: 1.98 USD
Trade Time: 4:00PM EST
Change: Down 0.02 (1.00%)
Prev Close: 2.00
Open: 1.99
Bid: N/A
Ask: 2.00 x 100
1y Target Est: 4.00
Day's Range: 1.94 - 2.00
52wk Range: 0.55 - 3.57
Volume: 287,194
Avg Vol (3m): 837,775
Market Cap: 76.63M
P/E (ttm): N/A
EPS (ttm): -0.78
Div & Yield: N/A (N/A%)
Cerus Corporation (CERS)
1d  5d  3m  6m  1y  2y  5y  max 
 Add CERS to Portfolio   Download Data

HEADLINES
• Biotech Stock Mailbag: FDA Playbook
at TheStreet.com (Fri, Nov 20)
• Biotech Stocks: Alkermes gains; Cerus, InterMune tumble
at MarketWatch (Tue, Nov 17)
• CERUS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Tue, Nov 17)
• UPDATE - US panel suggests stricter trial safety margins: Cerus
at Reuters (Tue, Nov 17)
• Playboy, Helicos: Early Volume Plays
at TheStreet.com (Tue, Nov 17)
• Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance for Proposed INTERCEPT Blood System Phase III Trial Design
Business Wire (Tue, Nov 17)
• Cerus Corporation Stock Trading Halted; FDA Blood Products Advisory Committee to Review and Discuss Proposed Phase III Clinical Trial Design for the I
Business Wire (Mon, Nov 16)
• Short Blood Supply Means Long Outlook for Cerus
at Seeking Alpha (Sun, Nov 15)
• CERUS CORP Financials
EDGAR Online Financials (Fri, Nov 13)
• CERUS CORP Files SEC form 10-Q, Quarterly Report
EDGAR Online (Fri, Nov 6)
• CERUS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Securit
EDGAR Online (Fri, Oct 30)
More Headlines for CERS...
ANALYST
EPS Est (next year) (Dec-09) : -0.66
EPS Est (in 2 years) (Dec-10) : -0.40
Avg Rec (current)*: 2.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System. The company’s INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components inten...

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices